AT
CRL icon

Arden Trust’s Charles River Laboratories CRL Stock Holding History

Arden Trust’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,168
Closed -$245K – 243
2023
Q2 		$245K Sell
1,168
-1,217
-51% -$242K 0.04% 217
2023
Q1 		$481K Buy
2,385
+361
+18% +$81.8K 0.09% 181
2022
Q4 		$441K Sell
2,024
-679
-25% -$148K 0.09% 185
2022
Q3 		$531K Buy
2,703
+299
+12% +$64.5K 0.13% 149
2022
Q2 		$515K Buy
2,404
+372
+18% +$90.9K 0.12% 164
2022
Q1 		$577K Buy
2,032
+216
+12% +$66.6K 0.11% 165
2021
Q4 		$684K Buy
+1,816
New +$706K 0.12% 166

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Arden Trust's CRL Position: Q3 2023 in Review

Arden Trust sold out of Charles River Laboratories (CRL) in Q3 2023, closing a stake of 1,168 shares — an estimated $245K sold.

Arden Trust first reported a position in CRL in Q4 2021 and held it in 7 quarters. The position peaked at $684K in Q4 2021. 621 funds tracked by Wall St. Rank hold CRL as of Q3 2023.

  • Arden Trust reported no remaining Charles River Laboratories position as of Q3 2023 after selling out during the quarter.
  • Arden Trust sold 1,168 Charles River Laboratories shares in Q3 2023, an estimated $245K.
  • Arden Trust first reported a position in Charles River Laboratories in Q4 2021 and held it in 7 quarters.
  • Arden Trust's Charles River Laboratories position peaked at $684K in Q4 2021.
  • 621 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2023.

Based on Arden Trust's 13F filing for Q3 2023, filed 10 Oct 2023.